Exposure‐response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma

Isatuximab is an approved anti‐CD38 monoclonal antibody with multiple antitumor modes of action. An exposure‐response (E‐R) analysis using data from patients with relapsed/refractory multiple myeloma (RRMM) enrolled in a phase Ib clinical study who received isatuximab at doses from 5 to 20 mg/kg wee...

Descripción completa

Detalles Bibliográficos
Autores principales: Rachedi, Fatiha, Koiwai, Kimiko, Gaudel‐Dedieu, Nadia, Sebastien, Bernard, Thai, Hoai‐Thu, Brillac, Claire, Fau, Jean Baptiste, Nguyen, Laurent, van de Velde, Helgi, Veyrat‐Follet, Christine, Semiond, Dorothée
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197531/
https://www.ncbi.nlm.nih.gov/pubmed/35355430
http://dx.doi.org/10.1002/psp4.12789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9197531/
https://www.ncbi.nlm.nih.gov/pubmed/35355430
http://dx.doi.org/10.1002/psp4.12789

Ejemplares similares